Literature DB >> 17475738

Medication access and continuity: the experiences of dual-eligible psychiatric patients during the first 4 months of the Medicare prescription drug benefit.

Joyce C West1, Joshua E Wilk, Irvin L Muszynski, Donald S Rae, Maritza Rubio-Stipec, Carol L Alter, William E Narrow, Darrel A Regier.   

Abstract

OBJECTIVE: This study attempted to systematically assess the experiences of Medicare and Medicaid "dual-eligible" psychiatric patients, including evaluating patients' access to medications and the administrative functioning of the program, during the first 4 months of the Medicare Part D prescription drug benefit.
METHOD: Psychiatrists (N=5,833) were randomly selected from the American Medical Association's Physicians Masterfile. After exclusion of those not practicing and with undeliverable addresses, 64% responded; 35% met study eligibility criteria of treating at least one dual-eligible patient during their last typical workweek and reported clinically detailed information on one systematically selected patient.
RESULTS: A total of 53.4% had at least one medication access problem to report between Jan. 1 and April 30, 2006. Although 9.7% experienced improved medication access, 22.3% discontinued or temporarily stopped taking medication because of prescription drug coverage or management issues, and 18.3% were previously stable but were required to switch medications. Among those with medication access problems, 27.3% experienced a significant adverse clinical event; 19.8% had an emergency room visit. Most drug plan features studied, including preferred drug/formulary lists, prior authorization, medication dosing/number limits, "fail-first" protocols, and requirements to switch to generics, were associated with significantly higher rates of medication access problems.
CONCLUSIONS: The findings indicate consequential medication access problems for psychiatric patients during the implementation of Medicare Part D. Although Centers for Medicare and Medicaid Services policies were enacted to ensure access to protected classes of psychopharmacologic medications, the high rates of medication access problems observed indicate further refinement of these policies is needed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475738     DOI: 10.1176/ajp.2007.164.5.789

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  13 in total

1.  Impact of Medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures.

Authors:  Anirban Basu; Wesley Yin; G Caleb Alexander
Journal:  Health Serv Res       Date:  2009-12-04       Impact factor: 3.402

Review 2.  Medicare Part D's effect on the under- and overuse of medications: a systematic review.

Authors:  Jennifer M Polinski; Julie M Donohue; Elaine Kilabuk; William H Shrank
Journal:  J Am Geriatr Soc       Date:  2011-08-01       Impact factor: 5.562

3.  The impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility.

Authors:  Frank Xiaoqing Liu; G Caleb Alexander; Stephanie Y Crawford; A Simon Pickard; Donald Hedeker; Surrey M Walton
Journal:  Health Serv Res       Date:  2011-05-24       Impact factor: 3.402

Review 4.  Changes in drug use and out-of-pocket costs associated with Medicare Part D implementation: a systematic review.

Authors:  Jennifer M Polinski; Elaine Kilabuk; Sebastian Schneeweiss; Troyen Brennan; William H Shrank
Journal:  J Am Geriatr Soc       Date:  2010-09       Impact factor: 5.562

5.  Roles of community helpers in using the Medicare Part D benefit.

Authors:  Melissa Anne Hensley
Journal:  J Health Care Poor Underserved       Date:  2011-02

Review 6.  Medicare Part D and quality of prescription medication use in older adults.

Authors:  Denys T Lau; Becky A Briesacher; Daniel R Touchette; JoAnn Stubbings; Judy H Ng
Journal:  Drugs Aging       Date:  2011-10-01       Impact factor: 3.923

7.  Entering and exiting the Medicare part D coverage gap: role of comorbidities and demographics.

Authors:  Susan L Ettner; Neil Steers; O Kenrik Duru; Norman Turk; Elaine Quiter; Julie Schmittdiel; Carol M Mangione
Journal:  J Gen Intern Med       Date:  2010-03-09       Impact factor: 5.128

8.  Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges.

Authors:  Stephen Crystal; Mark Olfson; Cecilia Huang; Harold Pincus; Tobias Gerhard
Journal:  Health Aff (Millwood)       Date:  2009-07-21       Impact factor: 6.301

9.  The effect of transitioning to medicare part d drug coverage in seniors dually eligible for medicare and medicaid.

Authors:  William H Shrank; Amanda R Patrick; Alex Pedan; Jennifer M Polinski; Laleh Varasteh; Raisa Levin; Nan Liu; Sebastian Schneeweiss
Journal:  J Am Geriatr Soc       Date:  2008-12       Impact factor: 5.562

10.  Revisiting practice-based research networks as a platform for mental health services research.

Authors:  J Curtis McMillen; Shannon L Lenze; Kristin M Hawley; Victoria A Osborne
Journal:  Adm Policy Ment Health       Date:  2009-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.